PerkinElmer announced plans to acquire Oxford Immunotec Global PLC, which specializes in proprietary test kits for latent tuberculosis, according to a press release.
Through this acquisition, PerkinElmer said it will grow its portfolio of advanced infectious-disease testing solutions to include tuberculosis. Moreover, the deal will enable PerkinElmer to combine its channel expertise and leading workflow and testing capabilities with Oxford Immunotec’s proficiencies in T cell immunology with its proprietary test kits for latent tuberculosis, PerkinElmer said in the release.
“Tuberculosis remains one of the leading infectious causes of death, with close to one quarter of the world’s population infected. Oxford Immunotec’s highly sensitive test and their team’s passion for solving complex health issues make it a natural fit with PerkinElmer’s mission and together, we believe will accelerate development of robust solutions to help detect infectious disease,” Prahlad Singh, PhD, President and Chief Executive Officer of PerkinElmer, said.
Based in Abingdon, United Kingdom, Oxford Immunotec had approximately 275 global employees as of September 30, 2020 and reported total revenue from continuing operations of $73.7 million and $39.2 million as of the fiscal year ended December 31, 2019 and the nine months ended September 30, 2020, respectively.
